New England Journal of Medicine· 2012Q1
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- 2,807citations
- Q1SCImago
- 2012year
Short summary
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival (16.5 vs. 8.3 months) and delayed chemotherapy initiation in men with metastatic castration-resistant prostate cancer who had not received prior chemotherapy.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine